Sai Life Sciences has disclosed its key performance indicators, revealing a significant revenue growth of 29.38% for fiscal 2026. The company’s revenue from operations reached ₹21,924.92 million, up from ₹16,945.70 million in the previous fiscal year.
The material margin also saw an increase, rising to ₹16,216.00 million, with a margin percentage of 73.96%. The EBITDA for fiscal 2026 was reported at ₹6,529.47 million, marking a year-on-year growth of 53.73%. The EBITDA margin improved to 29.78% from the previous fiscal’s 25.06%.
Profit before tax (PBT) and profit after tax (PAT) showed substantial growth, with PBT reaching ₹4,661.92 million and PAT at ₹3,489.10 million. This reflects a PAT year-on-year growth of 105.08% and a PAT margin of 15.91%.
The company’s return on capital employed (ROCE) and return on equity (ROE) for fiscal 2026 were 18.23% and 14.05%, respectively. The net debt to equity ratio stood at 0.01, while the net debt to EBITDA ratio was 0.04.
Sai Life Sciences also reported a decrease in net working capital days to 86 and inventory days to 86. The total number of scientific staff increased to 2,961.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).